Galera Therapeutics, Inc. (GRTX): Nasdaq/NYSE listing notice — Galera Therapeutics receives Nasdaq delisting notice for MVPHS non-compliance

Galera Therapeutics, Inc.

Nasdaq notified Galera on Sep 25, 2023 that MVPHS fell below $15M required for Global Market listing.
Company has 180 days, until March 25, 2024, to regain compliance by closing at $15M+ for 10 consecutive days.
May consider transferring to Nasdaq Capital Market if compliance cannot be met on Global Market.
Stock continues to trade under GRTX on Nasdaq Global Market; delisting risk if not cured by Compliance Date.
No assurance that compliance will be regained or that an appeal would succeed if delisting proceeds.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Galera Therapeutics, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(C)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: market value
Rules: 5450(b)(2)(C)

Exact text from the filing

September 25, 2023, Galera Therapeutics, Inc. (the “Company”) received written notice (the “Notice”) from The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that the Company is no longer in compliance with the minimum Market Value of Publicly Held Shares (“MVPHS”) of $15,000,000 required for continued listing on The Nasdaq Global Market as set forth in Nasdaq Listing Rule 5450(b)(2)(C) (the “Minimum MVPHS Requirement”). The Notice has no effect at this time on the listing of the Company’s common stock, par value $0.001 per share (“Common Stock”), which continues to trade on The Nasd

View on SEC.gov

8 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Galera Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-241844

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.